Merck Inc.,has announced findings from two additional Phase III studies evaluating the safety, tolerability and immunogenicity of V 114, the company’s investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study , healthy adults 50 years of age or older received V 114 or PCV 13 followed by Pneumovax 23 one year later.
Merck Inc announced findings from two additional Phase III studies evaluating the safety, tolerability and immunogenicity of V 114 (PVC 15), the company’s investigational 15-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease.
Pneumococcal polysaccharide vaccine is recommended for active immunisation against pneumococcal disease in children aged from 2 years, adolescents and adults. See section 5.1 for information on protection against specific pneumococcal serotypes.
Merck Inc announced results from two initial Phase III studies evaluating the safety, tolerability and immunogenicity of V 114, the company’s investigational 15-valent pneumococcal conjugate vaccine for pneumococcal disease.
Merck announced the FDA accepted for priority review a Biologics License Application (BLA) for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older.
Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes. Apexxnar should be used in accordance with official recommendations.
Pfizer Inc. announced at the end of 2018, the initiation of a Phase III program for its 20-Valent pneumococcal conjugate...
The FDA on 23 July 2012 approved Tudorza Pressair (aclidinium bromide) from Forest Pharma for the long-term maintenance treatment of...
Bristol-Myers Squibb Company announced data from multiple studies evaluating lisocabtagene maraleucel (liso-cel), an investigational CD19-directed CAR T-cell therapy with a...